SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Clinical researchers race against an invisible clock to discover mutations responsible for complex diseases such as cancer, Alzheimer’s, and autoimmune disorders that afflict their patients. They often use bulk exome sequencing to identify the genetic changes that trigger the disease’s onset; however, the mutations found to date do not adequately explain the origin or reoccurrence of disease. Fluidigm’s newest application, Single-Cell Whole Exome Sequencing workflow for its C1TM Single-Cell Auto Prep System, is designed to help researchers accelerate the discovery of novel functional variants that may alter protein function.
Help employers find you! Check out all the jobs and post your resume.
